Clinical Trial Results:
A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12
Months
Summary
|
|
EudraCT number |
2010-021491-28 |
Trial protocol |
FI SE IT |
Global end of trial date |
09 Oct 2013
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
15 Nov 2019
|
First version publication date |
02 Aug 2015
|
Other versions |
v1 |
Version creation reason |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
V419-008
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01480258 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Merck, Sharp & Dohme Corp.
|
||
Sponsor organisation address |
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
|
||
Public contact |
Clinical Trials Disclosure, Merck, Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Scientific contact |
Clinical Trials Disclosure, Merck, Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-000394-PIP01-08 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Oct 2013
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Oct 2013
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Oct 2013
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine. This study will also determine whether the immune response to V419 is similar to that of participants who received a licensed vaccine control. The primary hypothesis is that participants who receive PR5I at 2, 4, and 11 to 12 months have an acceptable response rate to all PR5I-contained antigens at one month after the toddler dose of PR5I.
|
||
Protection of trial subjects |
This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
The following additional measures defined for this individual study were in place for the protection of trial subjects: After each vaccination, participants were kept under observation for 30 minutes to ensure their safety. Adequate treatment provisions, including epinephrine, were available for immediate use in case of anaphylactic or anaphylactoid reactions occurring during or immediately following vaccination.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
23 Nov 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Finland: 919
|
||
Country: Number of subjects enrolled |
Italy: 264
|
||
Country: Number of subjects enrolled |
Sweden: 132
|
||
Worldwide total number of subjects |
1315
|
||
EEA total number of subjects |
1315
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
1315
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
Participants from Italy and Sweden were randomized to Rotavirus Vaccine Subset 1 (Rotarix™). Participants from Finland were randomized to Rotavirus Vaccine Subset 2 (RotaTeq™). | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
1325 participants were screened. 1315 participants were randomised. 1312 participants were vaccinated. 1300 participants received the 2 doses of the infant series (period 1). 1281 participants received the toddler dose (period 2). | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Infant Series
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
PR5I | ||||||||||||||||||||||||||||||
Arm description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
PR5I
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
V419 Vaxelis®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis [acellular, component], hepatitis B [recombinant DNA], polio virus [inactivated], and Haemophilus influenza type b conjugate vaccine [adsorbed]) Vaccine 0.5 mL intramuscular injection at 2 and 4 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Prevenar 13™
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Prevenar 13™ 0.5 mL intramuscular injection at 2 and 4 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Rotavirus vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Rotarix™
RotaTeq™
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Oral solution
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1,
Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
|
||||||||||||||||||||||||||||||
Arm title
|
INFANRIX™ hexa | ||||||||||||||||||||||||||||||
Arm description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Combined Diphtheria-Tetanus-acellular Pertussis [DTaP],
Hepatitis B [HepB], Poliovirus [IPV] and Haemophilus influenzae type b [Hib] Vaccine 0.5 mL intramuscular injection at 2 and 4 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB).
Prior to administration, the vaccine must be reconstituted by adding the liquid DTaPHepB-IPV component to the vial containing the Hib pellet.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Rotavirus vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Rotarix™ RotaTeq™
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Oral solution
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1,
Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Prevenar 13™
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Prevenar 13™ 0.5 mL intramuscular injection at 2 and 4 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||||||||
Period 2 title |
Interim Period
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
PR5I | ||||||||||||||||||||||||||||||
Arm description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||
Arm title
|
INFANRIX™ hexa | ||||||||||||||||||||||||||||||
Arm description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Period 3
|
|||||||||||||||||||||||||||||||
Period 3 title |
Toddler Dose
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
PR5I | ||||||||||||||||||||||||||||||
Arm description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Prevenar 13™
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Prevenar 13™ 0.5 mL intramuscular injection at 11 to 12 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
PR5I
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
V419 Vaxelis®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis [acellular, component], hepatitis B [recombinant DNA], polio virus [inactivated], and Haemophilus influenza type b conjugate vaccine [adsorbed]) Vaccine 0.5 mL intramuscular injection at 11 to 12 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
|
||||||||||||||||||||||||||||||
Arm title
|
INFANRIX™ hexa | ||||||||||||||||||||||||||||||
Arm description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Combined Diphtheria-Tetanus-acellular Pertussis [DTaP],
Hepatitis B [HepB], Poliovirus [IPV] and Haemophilus influenzae type b [Hib] Vaccine 0.5 mL intramuscular injection at 11 to 12 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB).
Prior to administration, the vaccine must be reconstituted by adding the liquid DTaPHepB-IPV component to the vial containing the Hib pellet.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Prevenar 13™
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Prevenar 13™ 0.5 mL intramuscular injection at 11 to 12 months of age.
Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
PR5I
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
PR5I
|
||
Reporting group description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||
Reporting group title |
INFANRIX™ hexa
|
||
Reporting group description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||
Reporting group title |
PR5I
|
||
Reporting group description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||
Reporting group title |
INFANRIX™ hexa
|
||
Reporting group description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||
Reporting group title |
PR5I
|
||
Reporting group description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||
Reporting group title |
INFANRIX™ hexa
|
||
Reporting group description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||
Subject analysis set title |
PR51
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age.
|
||
Subject analysis set title |
INFANRIX™ hexa
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age.
|
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Acceptability of antibody (Ab) response or seroresponse rates to all antigens contained in PR5I vaccine one month after the Toddler dose of PR5I (11 to 12 months of age) [1] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Acceptability response rates: Ab titre ≥1.0 μg/mL for Hib (polyribosylribitol phosphate, PRP); ≥10 mIU/mL for HBsAg; ≥0.1 IU/mL for diphtheria and tetanus; ≥8 (1/dil) for IPV type 1, 2 & 3, and percentage of pertussis seroresponder participants (Pertussis toxoid [PT], Filamentous haemagglutinin [FHA], Fimbriae types 2 & 3 [FIM] and Pertactin [PRN]) 1 month Post-Toddler PR51 dose. Seroresponse: (1) If pre-Dose 1 Ab concentration (cc) was <LLOQ (lower limit of quantitation), postvaccination Ab cc was ≥LLOQ, (2) If pre-Dose 1 Ab cc was ≥LLOQ, postvaccination Ab cc was ≥prevaccination levels. Analysis population: participants who met the inclusion criteria, were not protocol violators, received PR51 vaccinations within acceptable day ranges, and had a blood draw sample window of Days 28 to 51 following the Toddler dose. The analysis populations may not have been identical for each antigen-specific analysis at each post-vaccination visit.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
1 month after Toddler dose of PR51 (post-toddler dose)
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No between-group statistical analyses were performed for this endpoint. Single-sided analyses are presented on ClinicalTrials.gov NCT01480258. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Notes [2] - Participants receiving INFANRIX™ hexa were excluded from the acceptability analyses. |
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Non-inferiority of antibody (Ab) response rate to Haemophilus influenzae type b (PRP) one month after the 2nd dose of PR5I (4 months of age) as compared with INFANRIX hexa | ||||||||||||
End point description |
Percentage of participants with an Ab titre ≥1.0 μg/mL for Hib (polyribosylribitol phosphate, PRP) measured by radioimmunoassay (RIA) 1 month post-infant dose 2 of PR5I or INFANRIX hexa. Analysis population: participants who received 2nd dose in the Infant series and had a blood draw sample window of Days 28 to 51 post-infant dose 2.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
1 month after the 2nd dose (post-infant dose 2)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||
Number of subjects included in analysis |
1201
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [3] | ||||||||||||
P-value |
< 0.001 [4] | ||||||||||||
Method |
Miettinen & Nurminen | ||||||||||||
Parameter type |
Difference in percentages | ||||||||||||
Point estimate |
46.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
41.05 | ||||||||||||
upper limit |
51.06 | ||||||||||||
Notes [3] - If the lower bound of the 95% confidence interval (CI) was greater than -10% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [4] - Stratification by country. |
|
|||||||||||||
End point title |
Superiority of antibody (Ab) response rates to Haemophilus influenzae type b (PRP) one month after the 2nd dose of PR5I (4 months of age) as compared with INFANRIX hexa | ||||||||||||
End point description |
Percentage of participants with an Ab titre ≥1.0 μg/mL for Hib (polyribosylribitol phosphate, PRP) measured by RIA 1 month post-infant dose 2 of PR5I or INFANRIX hexa. Analysis population: participants who received 2nd dose in the Infant series and had a blood draw sample window of Days 28 to 51 post-infant dose 2.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
1 month after the 2nd dose (post-infant dose 2)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||
Number of subjects included in analysis |
1201
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [5] | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Miettinen & Nurminen | ||||||||||||
Parameter type |
Difference in percentages | ||||||||||||
Point estimate |
46.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
41.05 | ||||||||||||
upper limit |
51.06 | ||||||||||||
Notes [5] - If the lower bound of the 95% CI was greater than 0, it was concluded that PR5I group response rate was superior to INFANRIX hexa group response rate. |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Non-inferiority Ab response rates to PR5I antigens one month after the Toddler dose of PR5I (11 to 12 months of age) as compared with INFANRIX hexa | ||||||||||||||||||||||||||||||||||||||||||
End point description |
Percentage of participants with pre-specified Ab titre for PRP, HBsAg, diphtheria, tetanus, IPV1, 2 & 3, and percentage of pertussis seroresponder participants (PT, FHA, FIM and PRN) 1 month post-toddler dose were calculated based on the method by Miettinen and Nurminen stratified by country. Seroresponse was defined: (1) If pre-Dose 1 Ab cc was <LLOQ, post-vaccination Ab cc was ≥LLOQ, (2) If pre-Dose 1 Ab cc was ≥LLOQ, post-vaccination Ab cc was ≥pre-vaccination levels. Due to the timing of the occurrence of protocol violation or the availability of each antigen serology testing result, the analysis populations may not have been identical for each antigen-specific analysis at each post-vaccination visit. Analysis population: participants who met the inclusion criteria, were not protocol violators, received vaccinations within acceptable day ranges, and had a blood draw sample window of Days 28 to 51 following the Toddler dose.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
1 month after Toddler dose (post-toddler dose)
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of PRP
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [6] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [7] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-1.27
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-5.13 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
2.52 | ||||||||||||||||||||||||||||||||||||||||||
Notes [6] - The estimate of the difference between PR5I & INFANRIX hexa groups in PRP response rate (based on Ab titre ≥1.0 μg/mL) was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -10% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [7] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of HBsAg
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [8] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [9] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-0.59
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-2.66 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
1.35 | ||||||||||||||||||||||||||||||||||||||||||
Notes [8] - The estimate of the difference between PR5I & INFANRIX hexa groups in HBsAg response rate (based on Ab titre ≥10 mIU/mL) was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -10% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [9] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of diptheria
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [10] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [11] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-1.21
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-2.54 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
-0.22 | ||||||||||||||||||||||||||||||||||||||||||
Notes [10] - The estimate of the difference between PR5I & INFANRIX hexa groups in Diphtheria response rate (based on Ab titre ≥0.1 IU/mL) was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -10% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [11] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of tetanus
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [12] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [13] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-0.17
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-0.95 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
0.5 | ||||||||||||||||||||||||||||||||||||||||||
Notes [12] - The estimate of the difference between PR5I & INFANRIX hexa groups in Tetanus response rate (based on Ab titre ≥0.1 IU/mL) was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -5% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [13] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of PT
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [14] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [15] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-0.54
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-1.75 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
0.49 | ||||||||||||||||||||||||||||||||||||||||||
Notes [14] - The estimate of the difference between PR5I & INFANRIX hexa groups in the percentage of seroresponder participants for PT was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -10% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [15] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of FHA
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [16] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [17] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-1.73
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-3.47 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
-0.26 | ||||||||||||||||||||||||||||||||||||||||||
Notes [16] - The estimate of the difference between PR5I & INFANRIX hexa groups in the percentage of seroresponder participants for FHA was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -10% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [17] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of PRN
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [18] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [19] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-1.42
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-3.42 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
0.39 | ||||||||||||||||||||||||||||||||||||||||||
Notes [18] - The estimate of the difference between PR5I & INFANRIX hexa groups in the percentage of seroresponder participants for PRN was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -10% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [19] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of IPV1
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [20] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [21] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-0.51
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-1.59 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
0.34 | ||||||||||||||||||||||||||||||||||||||||||
Notes [20] - The estimate of the difference between PR5I & INFANRIX hexa groups in IPV1 response rate (based on Ab titre ≥8 (1/dil)) was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -5% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [21] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of IPV2
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [22] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [23] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-0.17
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-0.96 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
0.49 | ||||||||||||||||||||||||||||||||||||||||||
Notes [22] - The estimate of the difference between PR5I & INFANRIX hexa groups in IPV2 response rate (based on Ab titre ≥8 (1/dil)) was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -5% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [23] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of IPV3
|
||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1280
|
||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [24] | ||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.001 [25] | ||||||||||||||||||||||||||||||||||||||||||
Method |
Miettinen & Nurminen with stratification | ||||||||||||||||||||||||||||||||||||||||||
Parameter type |
Difference in percentages | ||||||||||||||||||||||||||||||||||||||||||
Point estimate |
-0.16
|
||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||||||||
lower limit |
-1.2 | ||||||||||||||||||||||||||||||||||||||||||
upper limit |
0.82 | ||||||||||||||||||||||||||||||||||||||||||
Notes [24] - The estimate of the difference between PR5I & INFANRIX hexa groups in IPV3 response rate (based on Ab titre ≥8 (1/dil)) was calculated with its 1-sided P-value & 2-sided 95% CI. If the lower bound of the 95% CI was greater than -5% (non-inferiority margin), it was concluded that PR5I group response rate was non-inferior to INFANRIX hexa group response rate. [25] - Statistical method was based on the Miettinen & Nurminen method stratified by country. |
|
|||||||||||||
End point title |
Non-inferiority of Rotavirus response (geometric mean titer, GMT) one month after the 2nd dose of Rotarix (4 months of age) administered concomitantly with PR5I versus INFANRIX hexa | ||||||||||||
End point description |
Antibody titres expressed in units/mL were measured for Rotavirus IgA by Enzyme Immunoassay (EIA), 1 month after the 2nd dose of Rotarix, administered concomitantly with PR5I or INFANRIX hexa (Post-Dose 2). The 95% CI for GMT was based on the t-distribution of the natural log-transformed antibody titer. Analysis population: participants who received dose 2 of Rotarix.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
1 month after the 2nd dose of Rotarix, administered concomitantly with PR5I or INFANRIX hexa (Post-Dose 2)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||
Comparison groups |
PR5I v INFANRIX™ hexa
|
||||||||||||
Number of subjects included in analysis |
331
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [26] | ||||||||||||
P-value |
= 0.011 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Geometric Mean Titre (GMT) ratio | ||||||||||||
Point estimate |
0.8
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.54 | ||||||||||||
upper limit |
1.2 | ||||||||||||
Notes [26] - The estimate for anti-rotavirus IgA GMT ratio (PR5I group/INFANRIX hexa group) was calculated with its 1-sided P-value and 2-sided 95% CI. If the lower bound of the 95% CI for GMT ratio was greater than 0.50 (non-inferiority margin), it was concluded that the Rotarix antigen response in the PR5I group was not inferior to the Rotarix antigen response in the INFANRIX hexa group. |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Number of participants who experienced an adverse event (AE) from Day 1 to Day 15 after any vaccination | ||||||||||||||||||||||||||||||||||||
End point description |
Injection-site and systemic AEs were reported daily on the Vaccination Report Card (VRC) by the parent(s) or legal representative from Day 1 (D1) to D15 after each vaccination. Solicited injection site and systemic AEs were reported daily from D1 to D5 after each vaccination. AEs at injection sites were always considered as vaccine-related (V-related) (Injection-Site Reactions [ISRs]). The investigator had to assess whether systemic AEs were related or not to the vaccine. All AEs (related and unrelated) are displayed here. Analysis population: all randomized participants who received at least 1 vaccination and who had safety follow-up.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Solicited AEs: up to 5 days (Days 1-5 after any vaccination); unsolicited AEs: up to 15 days (Day 1-15 after any vaccination)
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of ISR or systemic AE
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [27] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
0.3
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.7 | ||||||||||||||||||||||||||||||||||||
upper limit |
1.4 | ||||||||||||||||||||||||||||||||||||
Notes [27] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of V-related ISR or systemic AE
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [28] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
0.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.3 | ||||||||||||||||||||||||||||||||||||
upper limit |
2 | ||||||||||||||||||||||||||||||||||||
Notes [28] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of at least 1 ISR
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [29] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
2.6
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.7 | ||||||||||||||||||||||||||||||||||||
upper limit |
6 | ||||||||||||||||||||||||||||||||||||
Notes [29] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of at least 1 solicited ISR
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [30] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
2.5
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.9 | ||||||||||||||||||||||||||||||||||||
upper limit |
5.9 | ||||||||||||||||||||||||||||||||||||
Notes [30] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of at least 1 systemic AE
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [31] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
0.1
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-1.1 | ||||||||||||||||||||||||||||||||||||
upper limit |
1.4 | ||||||||||||||||||||||||||||||||||||
Notes [31] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of at least 1 vaccine-related systemic AE
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [32] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
0.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.5 | ||||||||||||||||||||||||||||||||||||
upper limit |
2.2 | ||||||||||||||||||||||||||||||||||||
Notes [32] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of at least 1 solicited systemic AE
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [33] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
0.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.5 | ||||||||||||||||||||||||||||||||||||
upper limit |
2.2 | ||||||||||||||||||||||||||||||||||||
Notes [33] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of at least 1 vaccine-related solicited systemic AE
|
||||||||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
other [34] | ||||||||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||||||||
Point estimate |
0.9
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.4 | ||||||||||||||||||||||||||||||||||||
upper limit |
2.3 | ||||||||||||||||||||||||||||||||||||
Notes [34] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|
||||||||||||||||||||||
End point title |
Percentage of participants reporting solicited ISRs from D1 to D5 after any vaccination | |||||||||||||||||||||
End point description |
Adverse events at injection sites were always considered as related to vaccine (Injection-Site Reactions [ISRs]). Solicited ISRs were defined as injection-site erythema, injection-site pain, and injection-site swelling occurring from D1 to D5 after vaccination. Analysis population: all randomised participants who received at least 1 vaccination and who had safety follow-up.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Up to 5 days (Day 1 to Day 5 following vaccination)
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site erythema
|
|||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other [35] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||
Point estimate |
8.2
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
3 | |||||||||||||||||||||
upper limit |
13.3 | |||||||||||||||||||||
Notes [35] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate whether an overall trend of risk differences existed. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site pain
|
|||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other [36] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||
Point estimate |
3.4
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-1.5 | |||||||||||||||||||||
upper limit |
8.3 | |||||||||||||||||||||
Notes [36] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate whether an overall trend of risk differences existed. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site swelling
|
|||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other [37] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||
Point estimate |
7.5
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
2.1 | |||||||||||||||||||||
upper limit |
12.9 | |||||||||||||||||||||
Notes [37] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate whether an overall trend of risk differences existed. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
|
||||||||||||||||||||||||||||
End point title |
Percentage of participants reporting unsolicited ISRs from D1 to D15 after any vaccination | |||||||||||||||||||||||||||
End point description |
Adverse events at injection sites were always considered as related to vaccine (Injection-Site Reactions [ISRs]). Unsolicited ISRs occurring from Day 1 (D1) to D15 after any vaccination were reported daily on the VRC by the parent(s) or legal representative. Unsolicited ISRs with incidence ≥1% are reported below. Analysis population: all randomised participants who received at least 1 vaccination and who had safety follow-up.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
From D1 to D15 after any vaccination
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site bruising
|
|||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||
Analysis type |
other [38] | |||||||||||||||||||||||||||
Method |
||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||||||||
Point estimate |
-1.1
|
|||||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||||
lower limit |
-2.5 | |||||||||||||||||||||||||||
upper limit |
0.3 | |||||||||||||||||||||||||||
Notes [38] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site haemorrhage
|
|||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||
Analysis type |
other [39] | |||||||||||||||||||||||||||
Method |
||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||||||||
Point estimate |
0
|
|||||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||||
lower limit |
-1.5 | |||||||||||||||||||||||||||
upper limit |
1.6 | |||||||||||||||||||||||||||
Notes [39] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site induration
|
|||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||||||||
Method |
||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||||||||
Point estimate |
2.6
|
|||||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||||
lower limit |
-1.2 | |||||||||||||||||||||||||||
upper limit |
6.4 | |||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site nodule
|
|||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||
Analysis type |
other [40] | |||||||||||||||||||||||||||
Method |
||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||||||||
Point estimate |
0.3
|
|||||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||||
lower limit |
-0.8 | |||||||||||||||||||||||||||
upper limit |
1.5 | |||||||||||||||||||||||||||
Notes [40] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | |||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of injection-site warmth
|
|||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
|||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
|||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||
Analysis type |
other [41] | |||||||||||||||||||||||||||
Method |
||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||||||||
Point estimate |
1.1
|
|||||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||||
lower limit |
-0.4 | |||||||||||||||||||||||||||
upper limit |
2.7 | |||||||||||||||||||||||||||
Notes [41] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|
|||||||||||||||||||||||||||||||
End point title |
Percentage of participants reporting solicited adverse events (AEs) from D1 to D5 after any vaccination | ||||||||||||||||||||||||||||||
End point description |
Solicited systemic AEs were defined as crying, decreased appetite, irritability, pyrexia (rectal temperature ≥38.0°C), somnolence, and vomiting occurring from D1 to D5 after vaccination. The investigator had to assess whether these systemic AEs were related or not to the vaccines. All (related and unrelated) are displayed here. Analysis population: all randomised participants who received at least 1 vaccination and who had safety follow-up.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
Up to 5 days (from D1 to D5 after any vaccination)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of crying
|
||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other [42] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||
Point estimate |
2.2
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-1.3 | ||||||||||||||||||||||||||||||
upper limit |
5.7 | ||||||||||||||||||||||||||||||
Notes [42] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate whether an overall trend of risk differences existed. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of decreased appetite
|
||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other [43] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||
Point estimate |
3.6
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-1.6 | ||||||||||||||||||||||||||||||
upper limit |
8.8 | ||||||||||||||||||||||||||||||
Notes [43] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of irritability
|
||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other [44] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||
Point estimate |
2.2
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-1 | ||||||||||||||||||||||||||||||
upper limit |
5.4 | ||||||||||||||||||||||||||||||
Notes [44] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of pyrexia
|
||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other [45] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||
Point estimate |
6.4
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
1.5 | ||||||||||||||||||||||||||||||
upper limit |
11.3 | ||||||||||||||||||||||||||||||
Notes [45] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of somnolence
|
||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other [46] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||
Point estimate |
5.8
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
1.7 | ||||||||||||||||||||||||||||||
upper limit |
9.8 | ||||||||||||||||||||||||||||||
Notes [46] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. The aim of the 95% CI was to investigate an overall trend and not any specific difference. If 0.0 was excluded from the 95% CI, the trend could not be ruled out. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Between group comparison | ||||||||||||||||||||||||||||||
Statistical analysis description |
Between group comparison of vomiting
|
||||||||||||||||||||||||||||||
Comparison groups |
PR51 v INFANRIX™ hexa
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1312
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other [47] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||||||||||||||
Point estimate |
1.8
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-3.2 | ||||||||||||||||||||||||||||||
upper limit |
6.9 | ||||||||||||||||||||||||||||||
Notes [47] - The risk differences between groups (PR5I group – INFANRIX hexa group) and their 2-sided 95% CI were calculated for the above criteria based on the unstratified Miettinen & Nurminen method. If the 95% CI for the risk differences included 0.0, the numerical differences were not considered significant. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to approximately 11 months. Serious AEs and deaths were collected for the duration of the study; unsolicited AEs were collected from D1 to D15 after each hexavalent vaccination, solicited AEs were collected D1 to D5 after each hexavalent vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Analysis population includes all randomised participants who received at least 1 vaccination and had safety follow-up.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
PR5I
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
INFANRIX™ hexa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]). Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 2.5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 Apr 2011 |
Amendment 1:The primary reasons for this amendment was (1) to designate that a subset of participants would receive Rotarix™ concomitantly with PR5I or INFANRIX hexa, while another subset of participants would receive RotaTeq™ concomitantly with PR5I or INFANRIX hexa; (2) revise the power statement for the secondary hypothesis for Rotarix™ immunogenicity; and (3) indicate that RotaTeq™ was to be administered at 2, 4, and 5 months of age. |
||
13 May 2011 |
Amendment 2: The primary reason for this amendment was to designate that RotaTeq™ was to be supplied centrally by Merck. |
||
20 Jan 2012 |
Amendment 3: The primary reason for this amendment was to allow the first dose of RotaTeq™ to be given in Finland prior to Visit 1 outside the study. |
||
26 Apr 2013 |
Amendment 5: The primary reason for this amendment was to revise the statistical analysis plan. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |